Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Copyright 2023 – Finance News Network
Source: Finance News Network
27 Aug 2020 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig talks about FY20 results, the impact of COVID-19 on clients' marketing spend, group strategy and outlook.
Read More17 May 2024 - Elementos Limited (ASX:ELT) Managing Director Joe David discusses the recommencement of DFS and licensing activities following discussions with the Andalusian government.
Read More01 Oct 2024 - Hazer Group Limited (ASX:HZR) CEO Glenn Corrie provides an update on the company, discussing IP protection and moving into commercialisation.
Read More20 May 2021 - Complii FinTech Solutions Limited (ASX:CF1) Executive Chairman Craig Mason talks about how the company's digital platform provides an electronic centralised framework to manage AFSL-centric (Stockbroker/Financial Planner/Adviser) workflows for compliance, capital raising and operational efficiencies.
Read More27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
Read More03 Nov 2023 - NOVONIX (ASX:NVX) CEO, Chris Burns, discusses securing a $100 million grant from the DOE, the company's Riverside facility expansion, graphite's future amidst China's export controls, and the pivotal role of synthetic graphite in clean energy.
Read More05 Feb 2021 - Centuria Office REIT (ASX:COF) Fund Manager Grant Nichols discusses 1H21 highlights, the market conditions for leasing, and the outlook and trends for office markets.
Read More29 Aug 2025 - Expanding technology and market reach
Read More10 May 2024 - Exploring tin's revival: Elementos CEO & MD Joe David discusses market trends and project developments.
Read More26 May 2025 - Strong results in soft tissue sarcoma have capped off a busy quarter of immunotherapy progress
Read More
